Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
24,446 total articles
Verisk Analytics reported Q2 2026 revenue of $806 million, up 4.3% reported and 5.8% on an organic constant currency basis. Adjusted EBITDA rose 4.2%, and adjusted diluted EPS increased 5.3% to $1.98, highlighting operational strength despite a net income decline due to higher taxes, interest expense, and legal fees. The company emphasized ongoing …
Anika Therapeutics, a leader in osteoarthritis pain management and orthopedic regenerative solutions, announced strong Q2 2026 financial results with record Commercial Channel revenue growth of 17% to $13.9 million, gross margin expansion to 65%, and adjusted EBITDA of $7.1 million, the highest since 2020. The company raised its full-year 2026 reve…
Axogen, Inc., a leader in peripheral nerve repair solutions, reported Q2 2026 revenue of $69.7 million, up 23.1% year-over-year. Despite a GAAP net loss of $1.5 million, adjusted net income increased to $7.3 million. The company is advancing clinical studies providing Level 1 evidence for its nerve repair products and expanded commercial coverage. …
uniQure announced its Q2 2026 financial results highlighting progress on AMT-130 for Huntington's disease with planned BLA submission in Q3 2026 following positive FDA interaction, four-year Phase I/II data expected September 2026, and ongoing development of other pipeline candidates including AMT-260 for epilepsy. The company completed a $259 mill…
Ocugen announced the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its gene therapy candidate OCU410 aimed at treating geographic atrophy secondary to dry age-related macular degeneration (dAMD). The designation supports expedited development and regulatory review due to promising Phase 2 clinical data demonstrating e…
Option Care Health, Inc., the largest independent provider of home and alternate site infusion services, reported Q2 2026 financial results showing 1.9% net revenue growth year-over-year to $1.442 billion and a 12.9% increase in GAAP diluted earnings per share to $0.35. Adjusted EBITDA rose 3.0% to $117.5 million, supported by operational execution…
Lightbridge Corporation, a developer of advanced nuclear fuel technology, announced its inclusion in the Solactive Global Uranium & Nuclear Components Total Return Index effective August 3, 2026. This index is tracked by the Global X Uranium ETF, providing investors passive exposure to the uranium and nuclear sector. The addition places Lightbridge…
Energous Corporation's PowerBridge Pro+ transmitter has received FCC certification, marking a key regulatory milestone for its wireless power solution. This allows Energous to commercially deploy its end-to-end, battery-free IoT wireless power network infrastructure in U.S. enterprise settings, including warehouses, logistics, manufacturing, and co…
Lumexa Imaging, a leading US outpatient imaging services provider, announced it will release its Q2 2026 financial and operational results after market close on August 12, 2026, followed by a conference call and webcast for investors and analysts.
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company focused on therapies for gout and kidney disease, announced the appointment of Depesh Narotam as an independent director on its board. Mr. Narotam brings over 20 years of financial services experience and will serve on the Compensation, Governance and Nominating Committee. The co…
Amarin Corporation plc announced its Q2 2026 financial results highlighting a 59% year-over-year global volume growth driven by its fully partnered international commercial strategy with Recordati S.p.A. and sustained market presence in the U.S. for VASCEPA. The company achieved lower operating expenses by 38%, completed a $70 million annual cost s…
Aclarion, Inc. reported significant progress in the first half of 2026, including a 141% year-over-year increase in scan volume, reimbursement gains in the U.K., a new U.S. Market Access Program partnership, advancement of the pivotal CLARITY trial, and strengthened patent portfolio. The company maintains a healthy balance sheet with $16.3 million …
TScan Therapeutics announced the dosing of the first patient in their Phase 3 ALLOHA-2 pivotal trial evaluating TSC-101, a TCR-engineered T cell therapy, in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) to prevent relapse post allogeneic hematopoietic cell transplantation. Positive safety and efficacy data from the …
ADMA Biologics, a U.S.-based biopharmaceutical company specializing in plasma-derived specialty biologics for immune deficiencies and infectious diseases, will report its second quarter 2026 financial results on August 5, 2026. The company will host a live conference call and webcast to discuss financial outcomes and corporate updates.
Aurora Mobile Limited announced that its AI-driven customer engagement platform, EngageLab, has been instrumental for Snapmaker in overcoming global communication challenges. By integrating EngageLab's AppPush service, Snapmaker has enhanced the efficiency, stability, and precision of its user reach worldwide, improving user retention and reinforci…
Capital Bancorp, Inc. (NASDAQ: CBNK) announced the appointment of James 'Jay' Como III as Chief Operating Officer of its subsidiary, Capital Bank. Mr. Como brings over 20 years of financial services leadership with expertise in data governance, automation, and AI from his prior roles at T. Rowe Price and Silicon Valley Bank. His leadership is expec…
Ceribell, Inc., a U.S.-based medical technology company specializing in point-of-care brain monitoring, announced the appointment of Thomas West and Sharon O’Keefe to its Board of Directors. The additions bring extensive commercial and health system leadership experience as Ceribell expands adoption of its brain monitoring platform in over 680 U.S.…
Aquestive Therapeutics will report its second quarter 2026 financial results after market close on August 11, 2026, followed by an investor conference call on August 12. The company will update on business developments including advancements in its proprietary Anaphylm and AQST-108 drug candidates. Aquestive operates as both a developer of propriet…
Silexion Therapeutics Corp. has initiated the Phase 2/3 clinical trial of its lead siRNA product candidate, SIL204, targeting locally advanced pancreatic cancer at Tel Aviv Sourasky Medical Center. This milestone follows regulatory approvals in Israel and Germany and marks the transition from regulatory preparation to active clinical execution. The…
Teva Pharmaceutical Industries Ltd. announced its Q2 2026 results showing a 1% revenue decline year-over-year primarily due to lower generic revenues but a 43% local currency growth in its key innovative brands to over $1 billion, including strong performances from AUSTEDO, AJOVY, and UZEDY. The company raised its 2026 revenue outlook for these inn…
VisionWave Holdings, Inc. announced the filing of a U.S. non-provisional patent application for its DeepWave RF™, an AI-driven subsurface sensing and visualization technology designed to provide anticipatory geological formation data ahead of the drill bit. This innovation aims to enhance drilling operations, improve hazard detection, and assist in…
VERAXA Biotech AG announced the filing of new patent applications for its BiTAC-TCE and BiTAC-ADC technology platforms and confirmed previously granted patents have cleared opposition. The strengthened patent portfolio includes over 50 patents across 14 countries and aims to provide protection for its core cancer therapy technologies through at lea…
AmpliTech Group, a US-based designer and manufacturer of advanced RF and microwave components including 5G infrastructure systems, secured over $6 million in follow-on orders during July 2026. These orders include nearly $4 million under a previously announced Letter of Intent with a North American mobile network operator and involve products certi…
Kirby Corporation reported Q2 2026 earnings per share of $1.67, consistent with the prior year and up 11% sequentially, with total revenues increasing 8% year-over-year to $922.4 million. The marine transportation segment saw revenues rise 9% due to stronger inland and coastal market fundamentals and higher barge utilization. Distribution and servi…
Capital Clean Energy Carriers Corp. (NASDAQ: CCEC) announced its second quarter 2026 financial results, highlighting delivery of multiple LNG and gas carriers, formation of joint ventures, secured long-term charters, and initiation of a $20 million share repurchase program. The company reported increased revenues and a stable net income despite hig…
